Aster DM Healthcare Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025, alongside several strategic board decisions that underscore the company's growth trajectory and operational restructuring initiatives. The company demonstrated strong operational performance with consolidated EBITDA reaching ₹212 crores compared to ₹190 crores in the previous year.

Financial Performance Highlights

The company delivered mixed financial performance across both standalone and consolidated operations during Q3FY26, with revenue growth and improved EBITDA performance, though margin pressures were evident.

Consolidated EBITDA Performance

The consolidated EBITDA growth of 11.58% to ₹212 crores reflects the company's operational efficiency improvements, though the EBITDA margin contracted slightly to 17.88% from 18.00% in the previous year.

Standalone Results

For the nine months ended December 31, 2025, standalone revenue from operations reached ₹1,960.60 crores compared to ₹1,746.62 crores in the corresponding previous period, while net profit stood at ₹240.36 crores. On a consolidated basis for nine months, revenue from operations increased to ₹3,460.84 crores from ₹3,138.12 crores in the previous year, with net profit attributable to owners reaching ₹247.97 crores.

Strategic Board Decisions

The Board of Directors, meeting on January 30, 2026, approved several significant strategic initiatives that will shape the company's future operations.

ESOP Scheme 2026 Approval

The scheme requires shareholder approval and will benefit eligible employees of the company, its unlisted subsidiaries, and unlisted holding company.

Internal Capital Restructuring

The company approved the conversion of inter-corporate loan into equity shares of its wholly owned subsidiary.

This restructuring forms part of the company's internal capital optimization strategy and does not affect the ownership or control of the subsidiary.

Strategic Acquisition and Merger Updates

During the reporting period, the company strengthened its subsidiary portfolio by acquiring an additional 5.02% stake in Prerana Hospital Limited (Aster Aadhar) for ₹18.59 crores, increasing shareholding from 93.90% to 98.92%. The company continues to progress with its merger plans involving Quality Care India Limited, having submitted the Scheme of Amalgamation to the National Company Law Tribunal (NCLT) on December 11, 2025, with creditor and shareholder meetings scheduled between February 27, 2026 to March 13, 2026.

Aster DM Healthcare Limited announced a strategic move to consolidate its ownership in material subsidiary Malabar Institute of Medical Sciences Limited (MIMS) through the acquisition of additional equity shares. The company's Investment and Finance Committee approved this proposal during its meeting held on January 29, 2026.

Acquisition Structure and Shareholding Consolidation

The proposed acquisition is designed to increase Aster DM Healthcare's shareholding in MIMS from the current 79.75% to 100%. The transaction involves purchasing an aggregate 20.25% of MIMS's equity share capital from existing shareholders through a structured letter of offer.

Transaction Timeline and Process

The acquisition process will commence with the dispatch of a letter of offer to MIMS shareholders, with the company estimating transaction completion within three months from the offer dispatch date. The actual number of shares to be purchased depends on the acceptance and participation of existing shareholders in the offer.

MIMS Financial Performance and Background

Malabar Institute of Medical Sciences Limited, established on February 17, 1995, operates in the healthcare services sector with a focus on hospital operations. The company is registered in Govindapuram P.O., Calicut, Kozhikode, Kerala, and operates exclusively within India.

As of March 31, 2025, MIMS reported a turnover of INR 1,118.05 crores and achieved a profit of INR 134.51 crores, demonstrating consistent growth in its healthcare operations.

Regulatory Compliance and Related Party Considerations

The proposed acquisition will not be classified as a related party transaction, as neither the promoters, promoter group, nor any group companies have interest in the entity being acquired. The transaction does not require specific governmental or regulatory approvals, streamlining the acquisition process.

Strategic Impact

This consolidation move aligns with Aster DM Healthcare's strategy to strengthen its control over key healthcare assets. The acquisition will provide complete ownership of MIMS, enhancing operational control and strategic decision-making capabilities within the healthcare services segment.